<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39371370</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2328-8957</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Open forum infectious diseases</Title><ISOAbbreviation>Open Forum Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Effectiveness of the First and Second Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Dose: A Nationwide Cohort Study From Austria on Hybrid Versus Natural Immunity.</ArticleTitle><Pagination><StartPage>ofae547</StartPage><MedlinePgn>ofae547</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">ofae547</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/ofid/ofae547</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">We aimed to evaluate the effectiveness of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccinations in previously SARS-CoV-2-infected adults in the general population of Austria during the Delta wave and with extended follow-up.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">In a nationwide retrospective cohort study, we calculated age-, sex-, and nursing home residency-adjusted Cox proportional hazard ratios (HRs) of coronavirus disease 2019 (COVID-19) deaths, SARS-CoV-2 infections, and non-COVID-19 deaths from 1 October to 31 December 2021, and secondarily with extended follow-up to 30 June 2022. Relative vaccine effectiveness (rVE) is rVE = (1 - HR) × 100.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Among 494 646 previously infected adults, 169 543 had received 2 vaccine doses, 133 567 had received 1 dose, and 190 275 were unvaccinated at baseline. We recorded 17 COVID-19 deaths (6 vaccinated, 11 unvaccinated) and 8209 SARS-CoV-2 infections. Absolute risk of COVID-19 deaths was 0.003%. rVE estimates for COVID-19 deaths and reinfections exceeded 75% until the end of 2021 but decreased substantially with extended follow-up. The risk of non-COVID-19 death was lower in those vaccinated versus unvaccinated.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">First and second SARS-CoV-2 vaccine doses appear effective in the short-term, but with diminishing effectiveness over time. The extremely low COVID-19 mortality, regardless of vaccination, indicates strong protection of previous infection against COVID-19 death. Lower non-COVID-19 mortality in the vaccinated population might suggest a healthy vaccinee bias.</AbstractText><CopyrightInformation>© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chalupka</LastName><ForeName>Alena</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Surveillance and Infectious Disease Epidemiology, Austrian Agency for Health and Food Safety, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riedmann</LastName><ForeName>Uwe</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richter</LastName><ForeName>Lukas</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute for Surveillance and Infectious Disease Epidemiology, Austrian Agency for Health and Food Safety, Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Statistics, Graz University of Technology, Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chakeri</LastName><ForeName>Ali</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute for Surveillance and Infectious Disease Epidemiology, Austrian Agency for Health and Food Safety, Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Public Health, Medical University Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El-Khatib</LastName><ForeName>Ziad</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Institute for Surveillance and Infectious Disease Epidemiology, Austrian Agency for Health and Food Safety, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sprenger</LastName><ForeName>Martin</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-7232-6515</Identifier><AffiliationInfo><Affiliation>Institute of Social Medicine and Epidemiology, Medical University Graz, Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Theiler-Schwetz</LastName><ForeName>Verena</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trummer</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Willeit</LastName><ForeName>Peter</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-1866-7159</Identifier><AffiliationInfo><Affiliation>Institute of Clinical Epidemiology, Public Health, Health Economics, Medical Statistics and Informatics, Medical University of Innsbruck, Innsbruck, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ignaz Semmelweis Institute, Interuniversity Institute for Infection Research, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schennach</LastName><ForeName>Harald</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Central Institute for Blood Transfusion and Department of Immunology, Tirol Kliniken GmbH, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benka</LastName><ForeName>Bernhard</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institute for Surveillance and Infectious Disease Epidemiology, Austrian Agency for Health and Food Safety, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Werber</LastName><ForeName>Dirk</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute for Surveillance and Infectious Disease Epidemiology, Austrian Agency for Health and Food Safety, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Høeg</LastName><ForeName>Tracy Beth</ForeName><Initials>TB</Initials><AffiliationInfo><Affiliation>Sloan School of Management, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Research, University of Southern Denmark, Odense, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ioannidis</LastName><ForeName>John P A</ForeName><Initials>JPA</Initials><AffiliationInfo><Affiliation>Departments of Medicine, Epidemiology and Population Health, Biomedical Data Science, and Statistics and Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pilz</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-7959-1311</Identifier><AffiliationInfo><Affiliation>Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Open Forum Infect Dis</MedlineTA><NlmUniqueID>101637045</NlmUniqueID><ISSNLinking>2328-8957</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">observational study</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList><CoiStatement>Potential conflicts of interest. All authors: No reported conflicts.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>11</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>11</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>5</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39371370</ArticleId><ArticleId IdType="pmc">PMC11450622</ArticleId><ArticleId IdType="doi">10.1093/ofid/ofae547</ArticleId><ArticleId IdType="pii">ofae547</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Watson  OJ, Barnsley  G, Toor  J, Hogan  AB, Winskill  P, Ghani  AC. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis  2022; 22:1293–302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9225255</ArticleId><ArticleId IdType="pubmed">35753318</ArticleId></ArticleIdList></Reference><Reference><Citation>Graña  C, Ghosn  L, Evrenoglou  T, et al.  Efficacy and safety of COVID-19 vaccines. Cochrane Database Syst Rev  2022; 12:Cd015477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9726273</ArticleId><ArticleId IdType="pubmed">36473651</ArticleId></ArticleIdList></Reference><Reference><Citation>Feikin  DR, Higdon  MM, Abu-Raddad  LJ, et al.  Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet  2022; 399:924–44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8863502</ArticleId><ArticleId IdType="pubmed">35202601</ArticleId></ArticleIdList></Reference><Reference><Citation>Flacco  ME, Acuti Martellucci  C, Baccolini  V, et al.  COVID-19 vaccines reduce the risk of SARS-CoV-2 reinfection and hospitalization: meta-analysis. Front Med (Lausanne)  2022; 9:1023507.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9681813</ArticleId><ArticleId IdType="pubmed">36438045</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg  Y, Mandel  M, Bar-On  YM, et al.  Protection and waning of natural and hybrid immunity to SARS-CoV-2. N Engl J Med  2022; 386:2201–12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9165562</ArticleId><ArticleId IdType="pubmed">35613036</ArticleId></ArticleIdList></Reference><Reference><Citation>Gazit  S, Shlezinger  R, Perez  G, et al.  The incidence of SARS-CoV-2 reinfection in persons with naturally acquired immunity with and without subsequent receipt of a single dose of BNT162b2 vaccine: a retrospective cohort study. Ann Intern Med  2022; 175:674–81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8855786</ArticleId><ArticleId IdType="pubmed">35157493</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen  KF, Moustsen-Helms  IR, Schelde  AB, et al.  Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: a Danish nationwide study. PLoS Med  2022; 19:e1004037.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9681105</ArticleId><ArticleId IdType="pubmed">36413551</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerqueira-Silva  T, Andrews  JR, Boaventura  VS, et al.  Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study. Lancet Infect Dis  2022; 22:791–801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8971277</ArticleId><ArticleId IdType="pubmed">35366959</ArticleId></ArticleIdList></Reference><Reference><Citation>Flacco  ME, Soldato  G, Acuti Martellucci  C, et al.  Risk of SARS-CoV-2 reinfection 18 months after primary infection: population-level observational study. Front Public Health  2022; 10:884121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9108359</ArticleId><ArticleId IdType="pubmed">35586006</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalupka  A, Richter  L, Chakeri  A, et al.  Effectiveness of a fourth SARS-CoV-2 vaccine dose in previously infected individuals from Austria. Eur J Clin Invest  2024; 54:e14136.</Citation><ArticleIdList><ArticleId IdType="pubmed">38032853</ArticleId></ArticleIdList></Reference><Reference><Citation>Høeg  TB, Duriseti  R, Prasad  V. Potential “healthy vaccinee bias” in a study of BNT162b2 vaccine against Covid-19. N Engl J Med  2023; 389:284–5.</Citation><ArticleIdList><ArticleId IdType="pubmed">37470285</ArticleId></ArticleIdList></Reference><Reference><Citation>Furst  T, Straka  R, Janosek  J. Healthy vaccinee effect: a bias not to be forgotten in observational studies on COVID-19 vaccine effectiveness. Pol Arch Intern Med  2024; 134:16634.</Citation><ArticleIdList><ArticleId IdType="pubmed">38415516</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilz  S, Chakeri  A, Ioannidis  JP, et al.  SARS-CoV-2 re-infection risk in Austria. Eur J Clin Invest  2021; 51:e13520.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7988582</ArticleId><ArticleId IdType="pubmed">33583018</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilz  S, Theiler-Schwetz  V, Trummer  C, Krause  R, Ioannidis  JPA. SARS-CoV-2 reinfections: overview of efficacy and duration of natural and hybrid immunity. Environ Res  2022; 209:112911.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8824301</ArticleId><ArticleId IdType="pubmed">35149106</ArticleId></ArticleIdList></Reference><Reference><Citation>Yahav  D, Yelin  D, Eckerle  I, et al.  Definitions for coronavirus disease 2019 reinfection, relapse and PCR re-positivity. Clin Microbiol Infect  2021; 27:315–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7718119</ArticleId><ArticleId IdType="pubmed">33285276</ArticleId></ArticleIdList></Reference><Reference><Citation>Pezzullo  AM, Axfors  C, Contopoulos-Ioannidis  DG, Apostolatos  A, Ioannidis  JPA. Age-stratified infection fatality rate of COVID-19 in the non-elderly population. Environ Res  2023; 216:114655.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9613797</ArticleId><ArticleId IdType="pubmed">36341800</ArticleId></ArticleIdList></Reference><Reference><Citation>Monge  S, Rojas-Benedicto  A, Olmedo  C, et al.  Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 Omicron (B.1.1.529) variant in Spain: a nationwide cohort study. Lancet Infect Dis  2022; 22:1313–20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9162477</ArticleId><ArticleId IdType="pubmed">35658998</ArticleId></ArticleIdList></Reference><Reference><Citation>Monge  S, Pastor-Barriuso  R, Hernán  MA. The imprinting effect of covid-19 vaccines: an expected selection bias in observational studies. BMJ  2023; 381:e074404.</Citation><ArticleIdList><ArticleId IdType="pubmed">37286211</ArticleId></ArticleIdList></Reference><Reference><Citation>R Core Team . R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2022.</Citation></Reference><Reference><Citation>COVID-19 Forecasting Team . Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis. Lancet  2023; 401:833–42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9998097</ArticleId><ArticleId IdType="pubmed">36930674</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilz  S, Ioannidis  JPA. Does natural and hybrid immunity obviate the need for frequent vaccine boosters against SARS-CoV-2 in the endemic phase?  Eur J Clin Invest  2023; 53:e13906.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9878177</ArticleId><ArticleId IdType="pubmed">36366946</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowe  B, Xie  Y, Al-Aly  Z. Postacute sequelae of COVID-19 at 2 years. Nat Med  2023; 29:2347–57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10504070</ArticleId><ArticleId IdType="pubmed">37605079</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowe  B, Xie  Y, Al-Aly  Z. Acute and postacute sequelae associated with SARS-CoV-2 reinfection. Nat Med  2022; 28:2398–405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9671810</ArticleId><ArticleId IdType="pubmed">36357676</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammerman  A, Sergienko  R, Friger  M, et al.  Effectiveness of the BNT162b2 vaccine after recovery from Covid-19. N Engl J Med  2022; 386:1221–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8908846</ArticleId><ArticleId IdType="pubmed">35172072</ArticleId></ArticleIdList></Reference><Reference><Citation>Powell  AA, Kirsebom  F, Stowe  J, et al.  Protection against symptomatic infection with Delta (B.1.617.2) and Omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021–March, 2022: a national, observational, test-negative, case-control study. Lancet Infect Dis  2023; 23:435–44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10032664</ArticleId><ArticleId IdType="pubmed">36436536</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordström  P, Ballin  M, Nordström  A. Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden. Lancet Infect Dis  2022; 22:781–90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8971363</ArticleId><ArticleId IdType="pubmed">35366962</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu  S, Huang  R, Sy  LS, et al.  COVID-19 vaccination and non-COVID-19 mortality risk—seven integrated health care organizations, United States, December 14, 2020–July 31, 2021. MMWR Morb Mortal Wkly Rep  2021; 70:1520–4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8553028</ArticleId><ArticleId IdType="pubmed">34710075</ArticleId></ArticleIdList></Reference><Reference><Citation>Barouch  DH. Covid-19 vaccines—immunity, variants, boosters. N Engl J Med  2022; 387:1011–20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9454645</ArticleId><ArticleId IdType="pubmed">36044620</ArticleId></ArticleIdList></Reference><Reference><Citation>Suthar  MS. Durability of immune responses to SARS-CoV-2 infection and vaccination. Semin Immunol  2024; 73:101884.</Citation><ArticleIdList><ArticleId IdType="pubmed">38861769</ArticleId></ArticleIdList></Reference><Reference><Citation>Lapuente  D, Winkler  TH, Tenbusch  M. B-cell and antibody responses to SARS-CoV-2: infection, vaccination, and hybrid immunity. Cell Mol Immunol  2024; 21:144–58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10805925</ArticleId><ArticleId IdType="pubmed">37945737</ArticleId></ArticleIdList></Reference><Reference><Citation>Uusküla  A, Pisarev  H, Tisler  A, et al.  Risk of SARS-CoV-2 infection and hospitalization in individuals with natural, vaccine-induced and hybrid immunity: a retrospective population-based cohort study from Estonia. Sci Rep  2023; 13:20347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10663482</ArticleId><ArticleId IdType="pubmed">37989858</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>